RECRUITING

Medical Cannabis in Patients With Advanced Pancreatic Cancer

Description

Many patients with Pancreatic Ductal Adenocarcinoma (PDAC) experience burdensome and difficult-to-treat symptoms. The impact of multiple symptoms (called "symptom burden") can negatively affect a patient's quality of life, decrease their ability to tolerate cancer treatments, and lead to worse survival. Current approaches to manage PDAC-associated symptoms often work poorly, with most patients reporting a moderate to severe symptom burden. Therefore, there is an urgent need for treatments that improve these symptoms in patients with PDAC, and data suggests that medical cannabis can help. In this research study, we are examining the usefulness of using medical cannabis in patients with pancreatic cancer to further study how cannabis can impact their symptom burden.

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)
Talk to us

Related Conditions:

Pancreatic Ductal Adenocarcinoma (PDAC)

Study Overview

On this page

Study Details

Study overview

Many patients with Pancreatic Ductal Adenocarcinoma (PDAC) experience burdensome and difficult-to-treat symptoms. The impact of multiple symptoms (called "symptom burden") can negatively affect a patient's quality of life, decrease their ability to tolerate cancer treatments, and lead to worse survival. Current approaches to manage PDAC-associated symptoms often work poorly, with most patients reporting a moderate to severe symptom burden. Therefore, there is an urgent need for treatments that improve these symptoms in patients with PDAC, and data suggests that medical cannabis can help. In this research study, we are examining the usefulness of using medical cannabis in patients with pancreatic cancer to further study how cannabis can impact their symptom burden.

A Randomized Phase II Trial of Medical Cannabis to Reduce Symptom Burden in Patients With Advanced Pancreatic Cancer (CanPan Trial)

Medical Cannabis in Patients With Advanced Pancreatic Cancer

Condition
Pancreatic Ductal Adenocarcinoma (PDAC)
Intervention / Treatment

-

Contacts and Locations

Saint Louis Park

HealthPartners Cancer Research Center, Saint Louis Park, Minnesota, United States, 55426

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adults (aged 18 or more at enrollment)
  • * Histologically or cytologically proven PDAC
  • * Advanced stage (locally advanced or metastatic) PDAC with no definitive plans for curative surgery in the next 4 months
  • * Self-report of experiencing nausea, vomiting, anorexia, cachexia (wasting), or pain at least once in the 14 days prior to randomization
  • * Plan to initiate or initiated within the past 2 weeks standard-of-care systemic chemotherapy (any regimen) at a participating institution with no prior systemic therapy in the prior 3 months (prior adjuvant or neoadjuvant chemotherapy is allowed as long as it was \>3 months prior to randomization)
  • * Must be a resident of Minnesota
  • * Must be willing to be registered in the Minnesota Medical Cannabis Program and follow all rules and requirements of the state program
  • * Must be willing to report baseline and required patient-reported outcomes
  • * Self-reported regular use (using 10 or more days in the 30 days prior to randomization) of a THC containing cannabinoid product
  • * Patients with a history of intolerance or hypersensitivity to cannabis (i.e., cannabis hyperemesis)
  • * Patients with Alzheimer's dementia, epilepsy, or history of traumatic brain injury
  • * Patients with known active or untreated brain metastases. A brain MRI is not required during the screening period
  • * Patients initiating or receiving immunotherapy or non-standard cytotoxic chemotherapy (including patients enrolled/ enrolling in trials of investigational cancer-directed treatments)
  • * Women who are pregnant, breastfeeding or of childbearing potential without the use of birth control
  • * Uncontrolled acute or chronic medical conditions, psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for enrollment in this study
  • * Has any condition that in the opinion of the investigator might jeopardize the safety of the subject or interfere with protocol compliance

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

HealthPartners Institute,

Study Record Dates

2026-12